{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:36:12Z","timestamp":1782815772549,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T00:00:00Z","timestamp":1573862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T00:00:00Z","timestamp":1573862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s40744-019-00181-8","type":"journal-article","created":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T11:01:57Z","timestamp":1573902117000},"page":"89-99","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population"],"prefix":"10.1007","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7556-8990","authenticated-orcid":false,"given":"Sara L.","family":"Gale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huong","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitya","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Jahreis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia J. F.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Sarsour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,16]]},"reference":[{"key":"181_CR1","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.berh.2010.10.007","volume":"24","author":"M Nikpour","year":"2010","unstructured":"Nikpour M, Stevens WM, Herrick AL, Proudman SM. Epidemiology of systemic sclerosis. Best Pract Res Clin Rheumatol. 2010;24:857\u201369.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"181_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.amjmed.2004.04.031","volume":"118","author":"JP Ioannidis","year":"2005","unstructured":"Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med. 2005;118:2\u201310.","journal-title":"Am J Med"},{"key":"181_CR3","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1002\/art.11073","volume":"48","author":"MD Mayes","year":"2003","unstructured":"Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48:2246\u201355.","journal-title":"Arthritis Rheum"},{"key":"181_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0889-857X(03)00022-X","volume":"29","author":"MD Mayes","year":"2003","unstructured":"Mayes MD. Scleroderma epidemiology. Rheum Dis Clin N Am. 2003;29:239\u201354.","journal-title":"Rheum Dis Clin N Am"},{"key":"181_CR5","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3899\/jrheum.111106","volume":"39","author":"DE Furst","year":"2012","unstructured":"Furst DE, Fernandes AW, Iorga SR, Greth W, Bancroft T. Epidemiology of systemic sclerosis in a large US managed care population. J Rheumatol. 2012;39:784\u20136.","journal-title":"J Rheumatol"},{"key":"181_CR6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/MD.0b013e318189372f","volume":"87","author":"MC Arias-Nunez","year":"2008","unstructured":"Arias-Nunez MC, Llorca J, Vazquez-Rodriguez TR, et al. Systemic sclerosis in northwestern Spain: a 19-year epidemiologic study. Medicine. 2008;87:272\u201380.","journal-title":"Medicine"},{"key":"181_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1046\/j.1445-5994.2001.00048.x","volume":"31","author":"PJ Roberts-Thomson","year":"2001","unstructured":"Roberts-Thomson PJ, Jones M, Hakendorf P, et al. Scleroderma in South Australia: epidemiological observations of possible pathogenic significance. Intern Med J. 2001;31:220\u20139.","journal-title":"Intern Med J"},{"key":"181_CR8","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/rheumatology\/27.4.286","volume":"27","author":"A Silman","year":"1988","unstructured":"Silman A, Jannini S, Symmons D, Bacon P. An epidemiological study of scleroderma in the West Midlands. Br J Rheumatol. 1988;27:286\u201390.","journal-title":"Br J Rheumatol"},{"key":"181_CR9","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1136\/ard.53.8.502","volume":"53","author":"AJ Geirsson","year":"1994","unstructured":"Geirsson AJ, Steinsson K, Guthmundsson S, Sigurthsson V. Systemic sclerosis in Iceland. A nationwide epidemiological study. Ann Rheum Dis. 1994;53:502\u20135.","journal-title":"Ann Rheum Dis"},{"key":"181_CR10","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1136\/annrheumdis-2013-203618","volume":"73","author":"K Andreasson","year":"2014","unstructured":"Andreasson K, Saxne T, Bergknut C, Hesselstrand R, Englund M. Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria. Ann Rheum Dis. 2014;73:1788\u201392.","journal-title":"Ann Rheum Dis"},{"key":"181_CR11","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/rheumatology\/kes076","volume":"51","author":"AM Hoffmann-Vold","year":"2012","unstructured":"Hoffmann-Vold AM, Midtvedt O, Molberg O, Garen T, Gran JT. Prevalence of systemic sclerosis in south-east Norway. Rheumatology. 2012;51:1600\u20135.","journal-title":"Rheumatology"},{"key":"181_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.semarthrit.2007.05.003","volume":"37","author":"H Chifflot","year":"2008","unstructured":"Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum. 2008;37:223\u201335.","journal-title":"Semin Arthritis Rheum"},{"key":"181_CR13","doi-asserted-by":"publisher","first-page":"186","DOI":"10.5301\/jsrd.5000207","volume":"1","author":"D Khanna","year":"2016","unstructured":"Khanna D, Distler JHW, Sandner P, Distler O. Emerging strategies for treatment of systemic sclerosis. J Scleroderma Relat Disord. 2016;1:186\u201393.","journal-title":"J Scleroderma Relat Disord"},{"key":"181_CR14","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1093\/rheumatology\/kew224","volume":"55","author":"CP Denton","year":"2016","unstructured":"Denton CP, Hughes M, Gak N, et al. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology. 2016;55:1906\u201310.","journal-title":"Rheumatology"},{"key":"181_CR15","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76:1327\u201339.","journal-title":"Ann Rheum Dis"},{"key":"181_CR16","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","volume":"44","author":"JE Pope","year":"2001","unstructured":"Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44:1351\u20138.","journal-title":"Arthritis Rheum"},{"key":"181_CR17","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655\u201366.","journal-title":"N Engl J Med"},{"key":"181_CR18","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/art.22204","volume":"54","author":"RK Hoyles","year":"2006","unstructured":"Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962\u201370.","journal-title":"Arthritis Rheum"},{"key":"181_CR19","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4:708\u201319.","journal-title":"Lancet Respir Med"},{"key":"181_CR20","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","volume":"378","author":"RK Burt","year":"2011","unstructured":"Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011;378:498\u2013506.","journal-title":"Lancet"},{"key":"181_CR21","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311:2490\u20138.","journal-title":"JAMA"},{"key":"181_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.semarthrit.2012.01.003","volume":"42","author":"KM Walker","year":"2012","unstructured":"Walker KM, Pope J. Treatment of systemic sclerosis complications: what to use when first-line treatment fails\u2013a consensus of systemic sclerosis experts. Semin Arthritis Rheum. 2012;42:42\u201355.","journal-title":"Semin Arthritis Rheum"},{"key":"181_CR23","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.2147\/DDDT.S99696","volume":"10","author":"LI Sakkas","year":"2016","unstructured":"Sakkas LI. Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis. Drug Des Dev Ther. 2016;10:2723\u20138.","journal-title":"Drug Des Dev Ther"},{"key":"181_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.mayocp.2013.01.018","volume":"88","author":"AA Shah","year":"2013","unstructured":"Shah AA, Wigley FM. My approach to the treatment of scleroderma. Mayo Clin Proc. 2013;88:377\u201393.","journal-title":"Mayo Clin Proc"},{"key":"181_CR25","first-page":"156","volume":"32","author":"SI Nihtyanova","year":"2014","unstructured":"Nihtyanova SI, Ong VH, Denton CP. Current management strategies for systemic sclerosis. Clin Exp Rheumatol. 2014;32:156\u201364.","journal-title":"Clin Exp Rheumatol"},{"key":"181_CR26","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/ard.2008.096677","volume":"68","author":"O Kowal-Bielecka","year":"2009","unstructured":"Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68:620\u20138.","journal-title":"Ann Rheum Dis"},{"key":"181_CR27","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3899\/jrheum.110121","volume":"39","author":"J Pope","year":"2012","unstructured":"Pope J, Harding S, Khimdas S, Bonner A, Baron M. Agreement with guidelines from a large database for management of systemic sclerosis: results from the Canadian Scleroderma Research Group. J Rheumatol. 2012;39:524\u201331.","journal-title":"J Rheumatol"},{"key":"181_CR28","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3899\/jrheum.170953","volume":"45","author":"S Alharbi","year":"2018","unstructured":"Alharbi S, Ahmad Z, Bookman AA, et al. Epidemiology and survival of systemic sclerosis-systemic lupus erythematosus overlap syndrome. J Rheumatol. 2018;45:1406\u201310.","journal-title":"J Rheumatol"},{"key":"181_CR29","doi-asserted-by":"publisher","first-page":"R54","DOI":"10.1186\/ar2965","volume":"12","author":"S Bosello","year":"2010","unstructured":"Bosello S, De Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther. 2010;12:R54.","journal-title":"Arthritis Res Ther"},{"key":"181_CR30","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","volume":"46","author":"D Daoussis","year":"2017","unstructured":"Daoussis D, Melissaropoulos K, Sakellaropoulos G, et al. A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum. 2017;46:625\u201331.","journal-title":"Semin Arthritis Rheum"},{"key":"181_CR31","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387:2630\u201340.","journal-title":"Lancet"},{"key":"181_CR32","unstructured":"Khanna D, Lin CJF, Kuwana M, et al. Efficacy and safety of tocilizuamb for the treatment of systemic sclerosis; results from a phase 3 randomized controlled trial [abstract]. Arthritis Rheum. 2018;70(suppl 10). https:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-of-tocilizumab-for-the-treatment-of-systemic-sclerosis-results-from-a-phase-3-randomized-controlled-trial\/. Accessed Sept 2, 2019."},{"key":"181_CR33","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380:2518\u201328.","journal-title":"N Engl J Med"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-019-00181-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-019-00181-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-019-00181-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T16:27:49Z","timestamp":1715185669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-019-00181-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,16]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["181"],"URL":"https:\/\/doi.org\/10.1007\/s40744-019-00181-8","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,16]]},"assertion":[{"value":"9 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}